Daclizumab meets in Phase III RRMS trial

Biogen Idec Inc. (NASDAQ:BIIB) and partner AbbVie Inc. (NYSE:ABBV) said once-monthly subcutaneous daclizumab ( DAC HYP) met the primary endpoint of reducing annualized relapse rate (ARR) vs. Biogen Idec's once-weekly Avonex interferon beta-1a in the Phase III DECIDE trial to treat relapsing-remitting multiple sclerosis (RRMS). Daclizumab reduced ARR by 45% compared to Avonex (p<0.0001). Daclizumab led to an increased incidence of serious infections, serious cutaneous reactions and elevations of liver transaminases vs. Avonex in the double-blind, international trial, which enrolled more than 1,800 RRMS patients. ...